Informations générales (source: ClinicalTrials.gov)
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. (PACT-01)
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
septembre 2021
septembre 2027
14 décembre 2024
Sequential comparative prospective interventional study evaluating the impact of the use
of an optimization device of the decision of cancer treatment on aggressiveness of end of
life care. Comparison between a first period, period (A), of care as usual and a second
period, period (B), of systematic and iterative use of a device for optimizing the
decision to continue an anti-cancer treatment.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/12/2024 12:44:18 | Contacter | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 04/12/2024 12:44:04 | Contacter | |||
| HOPITAL FOCH | ANNE CECILE METIVIER | 23/12/2024 08:04:29 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Bichat | Valérie GOUNANT, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Cochin | Marie WISLEZ, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Tenon | Vincent FALLET, MD | Contact (sur clinicalTrials) | |||
| CENTRE HOSPITALIER SUD FRANCILIEN | Marion LOZACH-BRUGIRARD, MD | Contact (sur clinicalTrials) | |||
| CHI DE CRETEIL | Isabelle MONNET, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP Ambroise Paré - 92100 - Boulogne-Billancourt - France | Etienne GIROUX-LEPRIEUR, MD | Contact (sur clinicalTrials) | |||
| Centre Léon Bérard - 69008 - Lyon - France | Bénédicte MASTROIANNI, MD | Contact (sur clinicalTrials) | |||
| CGFL - 21000 - Dijon - France | Aurélie LAGRANGE, MD | Contact (sur clinicalTrials) | |||
| CH Abbeville - 80142 - Abbeville - France | Olivier LELEU, MD | Contact (sur clinicalTrials) | |||
| CH du Pays d'Aix - 13616 - Aix-en-Provence - France | Stéphanie MARTINEZ, MD | Contact (sur clinicalTrials) | |||
| CH Henri Duffaut Avignon - 84000 - Avignon - France | Nicolas CLOAREC, MD | Contact (sur clinicalTrials) | |||
| CH Saint-Malo - 35420 - Saint-Malo - France | Marie TIERCIN, MD | Contact (sur clinicalTrials) | |||
| CHD Vendée - 85925 - La Roche-sur-Yon - France | Cyril GUIBERT, MD | Contact (sur clinicalTrials) | |||
| CHI de Compiègne-Noyon - 60200 - Compiègne - France | Stéphanie DEHETTE, MD | Contact (sur clinicalTrials) | |||
| CHR Metz-Thionville - Hôpital de Mercy - Ars-Laquenexy - France | Nadine PAILLOT, MD | Contact (sur clinicalTrials) | |||
| CHRU Lille - 59000 - Lille - France | Xavier DHALLUIN, MD | Contact (sur clinicalTrials) | |||
| CHU Amiens - Hôpital Sud - 80054 - Amiens - France | Claire POULET, MD | Contact (sur clinicalTrials) | |||
| CHU Angers - 49933 - Angers - France | José HUREAUX, MD | Contact (sur clinicalTrials) | |||
| CHU Grenoble Alpes - 38043 - Grenoble - France | Anne-Claire TOFFART, MD | Contact (sur clinicalTrials) | |||
| Clinique des Cèdres - 31700 - Cornebarrieu - France | Ioana CARPIUC, MD | Contact (sur clinicalTrials) | |||
| Clinique Tessier - 59300 - Valenciennes - France | HUET Dimitri, MD | Contact (sur clinicalTrials) | |||
| Institut Sainte-Catherine - 84918 - Avignon - France | Magali RAVOIRE, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Histologically or cytologically proven non-small-cell lung carcinoma (NSCLC)
including NSCLC with oncogene addiction.
2. Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015)
3. Patient having completed at least one line of chemotherapy in the context of
metastatic disease (or in the context of locoregional disease if the last
chemotherapy was less than 6 months ago).
4. ECOG Performance Status ≥ 2.
5. Age ≥ 18.
6. Written informed consent.
7. Patient capable, according to the investigator, to comply with the requirements of
the study.
1. Histologically or cytologically proven non-small-cell lung carcinoma (NSCLC)
including NSCLC with oncogene addiction.
2. Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015)
3. Patient having completed at least one line of chemotherapy in the context of
metastatic disease (or in the context of locoregional disease if the last
chemotherapy was less than 6 months ago).
4. ECOG Performance Status ≥ 2.
5. Age ≥ 18.
6. Written informed consent.
7. Patient capable, according to the investigator, to comply with the requirements of
the study.
1. Small Cell Lung Cancer (including mixed forms).
2. Patient with NSCLC for whom a decision has already been made to permanently
discontinue all systemic cancer treatment.
3. Impossible follow up for geographical, social or psychological reason.
4. Inability to answer a questionnaire (language or neurological barrier).
5. Patient under guardianship.
6. Patient being treated in a therapeutic trial.
7. Patient not covered by social security. -